N1,N12-Diacetylspermine as a Blood Based Lung Cancer Biomarker

Johannes F Fahrmann,Samir M Hanash

doi:10.4172/2161-1009.1000268

Abstract

It is becoming well recognized that metabolic perturbations are inherent hallmarks of tumorigenesis. Metabolites represent the functional products of cellular processes, which are highly responsive to both pathological and environmental stimuli. As such, metabolites are the closest representation of an individual’s current physiological state. Therefore, exploration of metabolic alterations in the context of disease pathophysiology, most notably cancer, holds great promise and considerable clinical value. This field of research has benefited from technological advances in mass spectrometry and ultraviolet-visible spectroscopic analyses that have enabled comprehensive metabolomic analyses of diverse arrays of metabolites, polyphenols and lipids in a variety of biological matrices with substantial robustness and sensitivity . As a result, interest in the application of metabolomics to identify key metabolic differences related to pathological conditions has expanded. Indeed, metabolomics has been explored to gain insights into the pathophysiology of cancer, develop methods predictive of disease onset, and reveal new biomarkers relevant to disease diagnosis and prognosis.

Highlights

It is becoming well recognized that metabolic perturbations are inherent hallmarks of tumorigenesis [1,2]
In our study we examined the performance of DAS in combination with another marker Pro-SFTPB, which we previously validated as a blood based marker for non-small cell lung cancer (NSCLC) [13]
The combination of DAS and Pro-SFTPB resulted in improved performance compared to either alone (Overall AUCs of 0.732, 0.650 and 0.699 in the validation set for Pro-SFTPB + DAS, DAS only and Pro-SFTPB only, respectively) [6]

Summary

Introduction

It is becoming well recognized that metabolic perturbations are inherent hallmarks of tumorigenesis [1,2]. Exploration of metabolic alterations in the context of disease pathophysiology, most notably cancer, holds great promise and considerable clinical value. The application of metabolomics to the discovery of blood-based biomarker in cancer has substantial potential clinical relevance.

Results

Conclusion